DETROL LA

LOE Approaching

tolterodine tartrate

NDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7

Mechanism of Action

receptors. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of 5-hydroxymethyl tolterodine (5-HMT), the major pharmacologically active metabolite. 5-HMT,…

Clinical Trials (5)

NCT01089751Phase 4Completed

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Started Mar 2010
322 enrolled
Overactive Bladder
NCT00768521Phase 1Completed

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

Started Sep 2008
20 enrolled
Overactive Bladder
NCT00411437Phase 4Completed

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Started Dec 2006
220 enrolled
MemoryCognition
NCT00230789Phase 4Completed

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

Started Oct 2005
417 enrolled
Urinary Incontinence
NCT00143481Phase 4Completed

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

Started Mar 2005
400 enrolled
Urinary Incontinence